![]() ![]() The antiviral drug has received emergency approval from the FDA, but for hospitalized coronavirus patients who are severely ill. Gottlieb said he thought that if Trump were going to receive any early treatments for Covid-19, it was likely to be Gilead Sciences ' remdesivir. The White House did not immediately respond to CNBC's request for comment on the decision to give Trump the antibody drug. Trump also has a low-grade fever, NBC News reported Friday afternoon, citing three people familiar with his condition. Sean Conley, said the president was given Regeneron's antibody cocktail "as a precautionary measure." Conley also wrote that Trump "remains fatigued but in good spirits." In a memo provided Friday by the White House, Trump's physician, Dr. The goal is to boost the immune system's defenses, rather than to wait on human biology to do its job. Regeneron's REGN-COV2 is an experimental shot of lab-generated antibodies that mimics how the body would mount a reaction to a foreign invader. Regeneron is not the only company developing antibody drugs Eli Lilly and GlaxoSmithKline also are testing monoclonal antibodies, which experts have viewed as a promising potential Covid-19 treatment. At the time, the company indicated it plans to "rapidly" discuss the early results with regulatory agencies, including the FDA. That was based on results for the first 275 trial patients. On Tuesday, Regeneron said its REGN-COV2 treatment improved symptoms and reduced viral loads in non-hospitalized patients who have mild to moderate Covid-19. Regeneron's antibody drug is still experimental and has not received emergency use approval from the FDA, but it was provided in response to a compassionate use request.ĬNBC's Meg Tirrell on Friday reported that a "limited number of patients" had also received the drug on that basis after speaking with Regeneron's chief scientific officer, Dr. Regeneron confirmed it provided a single, 8-gram dose of its REGN-COV2 treatment for use by the president, whose coronavirus diagnosis was announced just before 1 a.m. medicine doesn't mean better medicine when there is no data." On Twitter, as one doctor commented, "V.I.P. Some shared concerns about the preferential treatment provided to the president, as the drug has not been approved by federal regulators, and others pointed to the limited available data. ![]() Not everyone in the medical community agrees with Gottlieb about the decision to give Trump an experimental treatment. "I wouldn't infer anything from the fact they chose the Regeneron product over another product - other than they probably had confidence looking at the data on the Regeneron product that it seemed to be the most effective of the products, given what they knew," added Gottlieb, who led the regulatory agency under Trump from May 2017 to April 2019.
0 Comments
Leave a Reply. |